Belimumab clinical trials
Also written Benlysta, LymphoStat-B™ and HGS1006.
How each study uses belimumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the belimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Mar 2011 · BENLYSTA · BLA 125370 (FDA, Drugs@FDA)
- European Union
- 13 Jul 2011 · Benlysta · EMEA/H/C/002015 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 8 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 39 · Other 38
GlaxoSmithKline (22) · Human Genome Sciences Inc., a GSK Company (8) · Human Genome Sciences Inc. (8) · Leiden University Medical Center (3) · Peking Union Medical College Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Assistance Publique - Hôpitaux de Paris (3) · Hospital for Special Surgery, New York (2)
Often tested with
Tested in the same studies.
Rituximab (6) · Mycophenolic Acid (2) · GSK4527363 (1) · Candida albicans Antigen Injection (1) · Methotrexate (1) · Sulfasalazine (1) · Hydroxychloroquine (1) · Leflunomide (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test belimumab, phase 3 first.
- Nov 2026Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaPhase 3 · Assistance Publique - Hôpitaux de Paris
- Mar 2027Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- Jun 2027The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentPhase 2 · Nanjing University School of Medicine
- Jun 2027A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Phase 4 · GlaxoSmithKline
- Aug 2027Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisPhase 2 · Hospital for Special Surgery, New York
Studies
Open first, then newest update. How each study uses belimumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 77
- Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)RecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04097561Written as Belimumab
- Belimumab in Autoimmune HepatitisRecruitingPhase 2University Health Network, TorontoNCT06381453Written as Belimumab Auto-Injector [Benlysta]
- Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitizedRecruitingPhase 2Leiden University Medical CenterNCT07539857Written as Belimumab Prefilled Syringe [Benlysta]
- Belimumab With Rituximab for Primary Membranous NephropathyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03949855Written as Belimumab
- A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)RecruitingPhase 3GlaxoSmithKlineNCT06716606Written as Belimumab
- A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung DiseaseRecruitingPhase 2/3GlaxoSmithKlineNCT05878717Written as Belimumab
- A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue DiseaseRecruitingPhase 3GlaxoSmithKlineNCT06572384Written as Belimumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Belimumab
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingPhase 2Nanjing University School of MedicineNCT07340463Written as belimumab
- Effect of Belimumab on Antibody Titers in Primary APS PatientsRecruitingPhase 2Ruijin HospitalNCT06747312Written as Belimumab+SOC
- Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)RecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT04629144Written as Belimumab
- Belimumab After Rituximab in Resistant Primary Juvenile SSRecruitingPhase 4Peking Union Medical College HospitalNCT06410833Written as Belimumab
- A Model About the Response of Belimumab in SLENot yet recruitingPhase 4First Affiliated Hospital Xi'an Jiaotong UniversityNCT04893161Written as Belimumab
- Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT05338190Written as Combination of Rituximab with subcutaneous belimumab
- Sequential Belimumab and T-cell Based Therapy in SLERecruitingPhase 4National University Hospital, SingaporeNCT04447053Written as Belimumab Injection [Benlysta]
- Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus NephritisRecruitingPhase 3Nanjing University School of MedicineNCT05863936Written as Belimumab Injection
- A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsActive, not recruitingPhase 1GlaxoSmithKlineNCT06576271Written as Belimumab
- A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruitingPhase 4GlaxoSmithKlineNCT06411249Written as Belimumab (GSK1550188)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisActive, not recruitingPhase 2Hospital for Special Surgery, New YorkNCT03844061Written as Belimumab
- Synergetic B-cell Immunomodulation in SLE - 2nd Study.CompletedPhase 3Leiden University Medical CenterNCT03747159Written as Belimumab Injection
See all 77 studies that test belimumab →
Given beside what is tested · 1 — belimumab is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with belimumab
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT06857214Written as Belimumab
- Trial of Belimumab in Early LupusRecruitingPhase 4Northwell HealthNCT03543839Written as Belimumab
- Japanese phase1 Study of Belimumab (IV vs SC)CompletedPhase 1GlaxoSmithKlineNCT01516450Written as GSK1550188 IV
Codes
What other systems call belimumab · ClinicalTrials.gg INT004939
- MeSH (NLM) C511911belimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 73B0K5S26ABELIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1092437Confirmed FDA, Wikidata
- Wikidata Q1996249belimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91385BelimumabOne source FDA
- DrugBank DB08879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C511911 | belimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 73B0K5S26A | BELIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1092437 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1996249 | belimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91385 | Belimumab | One source FDA |
| DrugBank | DB08879 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.